Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Sorafenib tosylate may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow
to the tumor. It is not yet known whether cetuximab is more effective when given alone or
together with sorafenib tosylate in treating patients with head and neck cancer. This
randomized phase II trial is studying cetuximab to see how well it works when given together
with or without sorafenib tosylate in treating patients with refractory, recurrent, and/or
metastatic head and neck cancer.